Cargando…

Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis

Background: Several drugs currently are available for the treatment of Crohn's disease, including non-biological agents such as anti-inflammatory agents, steroids, immunosuppressive agents, and biologic agents such as anti-tumor necrosis factor (TNF), anti-α4β7 integrin, anti-alpha-4 integrin a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rui, Mingjun, Fei, Zhengyang, Wang, Yingcheng, Shi, Fenghao, Meng, Rui, Shang, Ye, Ma, Aixia, Li, Hongchao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440847/ https://www.ncbi.nlm.nih.gov/pubmed/34540859 http://dx.doi.org/10.3389/fmed.2021.679258

Ejemplares similares

Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China
por: Rui, Mingjun, et al.
Publicado: (2021)

The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: A Bayesian network meta-analysis
por: Meng, Rui, et al.
Publicado: (2022)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China
por: Rui, Mingjun, et al.
Publicado: (2022)

The effect of biological agent on body composition in patients with Crohn’s disease
por: Choi, Eun Jeong, et al.
Publicado: (2023)

Treatment of reactive arthritis with biological agents: a review
por: Zeng, Huiqiong, et al.
Publicado: (2020)

Lactobacillus GG in inducing and maintaining remission of Crohn's disease
por: Schultz, Michael, et al.
Publicado: (2004)

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
por: Ooi, Choon Jin, et al.
Publicado: (2019)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

5-Aminosalicylates to maintain remission in Crohn’s disease: Interpreting conflicting systematic review evidence
por: Gordon, Morris
Publicado: (2017)

Tapering of Biological Agents in Juvenile ERA Patients in Daily Clinical Practice
por: Liao, Chun-Hua, et al.
Publicado: (2021)

Biological Agents
por: Greaves, Ian, et al.
Publicado: (2010)

Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease
por: Sollelis, Elisa, et al.
Publicado: (2019)

Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
por: Robles-Alonso, Virginia, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective
por: Wang, Yingcheng, et al.
Publicado: (2021)

Biological drugs for inducing remission in patients with Crohn's disease: determining statistical equivalence according to evidence-based methods
por: Messori, Andrea, et al.
Publicado: (2015)

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
por: Gisbert, Javier P., et al.
Publicado: (2023)

Efficacy of Mycophenolate Mofetil as a Remission Maintaining Agent in Idiopathic Childhood Nephrotic Syndrome
por: Nandi, M., et al.
Publicado: (2019)

Biological warfare agents
por: Thavaselvam, Duraipandian, et al.
Publicado: (2010)

Biological Agents and Bioterrorism
por: Bologna, Mauro
Publicado: (2014)

Synthesis and biological evaluation of novel sinomenine derivatives as anti-inflammatory and analgesic agent
por: Gao, Feng, et al.
Publicado: (2022)

Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent
por: Woerner, A, et al.
Publicado: (2015)

Ustekinumab Successfully Treats and Maintains Remission of Pyostomatitis Vegetans Associated with Crohn’s Disease
por: Abi Doumeth, Sarah, et al.
Publicado: (2020)

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
por: Ghazawi, Feras M., et al.
Publicado: (2021)

Safety Prediction of Infants Born to Mothers with Crohn's Disease Treated with Biological Agents in the Late Gestation Period
por: Sako, Minako, et al.
Publicado: (2021)

Biologic Agents in Crohn's Patients Reduce CD4(+) T Cells Activation and Are Inversely Related to Treg Cells
por: Rosseto-Welter, Eliane Aparecida, et al.
Publicado: (2022)

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
por: Eriksson, Carl, et al.
Publicado: (2023)

Adverse Pregnancy Outcomes Following Exposure to Biologics in Women With Crohn's Disease: A Systematic Review and Meta-Analysis
por: Wang, Han, et al.
Publicado: (2021)

Chelating agents in biological systems.
por: Schubert, J
Publicado: (1981)

Biologic Agents and Disease Emergence
por: Potter, Polyxeni
Publicado: (2004)

Detecting Biological Warfare Agents
por: Song, Linan, et al.
Publicado: (2005)

Biologic agents in juvenile spondyloarthropathies
por: Katsicas, María Martha, et al.
Publicado: (2016)

Occupational Exposure to Biological Agents
por: Santos, Joana, et al.
Publicado: (2020)

Biological Agents and Terror Medicine
por: Oren, Meir
Publicado: (2009)

Introduction to Biological Agents and Pandemics
por: Kearney, Alexis, et al.
Publicado: (2016)

Biological Hazards and Select Agents
por: Stitt-Fisher, Molly
Publicado: (2015)

Synthesis and Biological Evaluation of Apigenin Derivatives as Antibacterial and Antiproliferative Agents
por: Liu, Rui, et al.
Publicado: (2013)

Low-dose azathioprine is effective in maintaining remission among Chinese patients with Crohn’s disease
por: Wu, Jianghong, et al.
Publicado: (2013)

Retraction: Adverse Pregnancy Outcomes Following Exposure to Biologics in Women With Crohn's Disease: A Systematic Review and Meta-Analysis
Publicado: (2022)

Design, Synthesis and Biological Evaluation of Some Triazole Schiff’s Base Derivatives as Potential Antitubercular Agents
por: Sager, Asma A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nrrfnug28padpnapofd47ueqem